117 related articles for article (PubMed ID: 16401350)
1. Adding pharmacogenomics to the development of new marine-derived anticancer agents.
Jimeno J; Aracil M; Tercero JC
J Transl Med; 2006 Jan; 4():3. PubMed ID: 16401350
[TBL] [Abstract][Full Text] [Related]
2. Progress in the clinical development of new marine-derived anticancer compounds.
Jimeno J; López-Martín JA; Ruiz-Casado A; Izquierdo MA; Scheuer PJ; Rinehart K
Anticancer Drugs; 2004 Apr; 15(4):321-9. PubMed ID: 15057135
[TBL] [Abstract][Full Text] [Related]
3. Kahalalide F and ES285: potent anticancer agents from marine molluscs.
Faircloth G; Cuevas C
Prog Mol Subcell Biol; 2006; 43():363-79. PubMed ID: 17153351
[TBL] [Abstract][Full Text] [Related]
4. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
5. In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells.
Gómez SG; Bueren JA; Faircloth GT; Jimeno J; Albella B
Exp Hematol; 2003 Nov; 31(11):1104-11. PubMed ID: 14585376
[TBL] [Abstract][Full Text] [Related]
6. A clinical armamentarium of marine-derived anti-cancer compounds.
Jimeno JM
Anticancer Drugs; 2002 May; 13 Suppl 1():S15-9. PubMed ID: 12173490
[TBL] [Abstract][Full Text] [Related]
7. Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicity.
Humeniuk R; Menon LG; Mishra PJ; Saydam G; Longo-Sorbello GS; Elisseyeff Y; Lewis LD; Aracil M; Jimeno J; Bertino JR; Banerjee D
Leukemia; 2007 Dec; 21(12):2399-405. PubMed ID: 17713546
[TBL] [Abstract][Full Text] [Related]
8. [Development of marine-derived anti-cancer compounds].
Taguchi T
Gan To Kagaku Ryoho; 2003 May; 30(5):579-88. PubMed ID: 12795086
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM
Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545
[TBL] [Abstract][Full Text] [Related]
10. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
11. Finding chemo: the search for marine-based pharmaceutical drugs active against cancer.
Indumathy S; Dass CR
J Pharm Pharmacol; 2013 Sep; 65(9):1280-301. PubMed ID: 23927467
[TBL] [Abstract][Full Text] [Related]
12. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
13. Preclinical and clinical results with the natural marine product ET-743.
D'Incalci M; Jimeno J
Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
[TBL] [Abstract][Full Text] [Related]
14. Convergent approaches for the synthesis of the antitumoral peptide, Kahalalide F. Study of orthogonal protecting groups.
Gracia C; Isidro-Llobet A; Cruz LJ; Acosta GA; Alvarez M; Cuevas C; Giralt E; Albericio F
J Org Chem; 2006 Sep; 71(19):7196-204. PubMed ID: 16958512
[TBL] [Abstract][Full Text] [Related]
15. Cancer treatments: can we find treasures at the bottom of the sea?
Provencio M; Sánchez A; Gasent J; Gómez P; Rosell R
Clin Lung Cancer; 2009 Jul; 10(4):295-300. PubMed ID: 19632950
[TBL] [Abstract][Full Text] [Related]
16. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.
Dal Lago L; D'Hondt V; Awada A
Oncologist; 2008 Aug; 13(8):845-58. PubMed ID: 18695262
[TBL] [Abstract][Full Text] [Related]
17. Multiple Myeloma: Possible Cure from the Sea.
Capalbo A; Lauritano C
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740630
[TBL] [Abstract][Full Text] [Related]
18. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
19. In vitro hemolysis and buffer capacity studies with the novel marine anticancer agent kahalalide F and its reconstitution vehicle cremophor EL/ethanol.
Nuijen B; Bouma M; Manada C; Jimeno JM; Bult A; Beijnen JH
PDA J Pharm Sci Technol; 2001; 55(4):223-9. PubMed ID: 11505554
[TBL] [Abstract][Full Text] [Related]
20. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions.
Gasparini G; Longo R; Fanelli M; Teicher BA
J Clin Oncol; 2005 Feb; 23(6):1295-311. PubMed ID: 15718328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
